We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+83.78%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.12B
AUM Growth
+$212M
Cap. Flow
-$46.3M
Cap. Flow %
-4.15%
Top 10 Hldgs %
42.31%
Holding
75
New
24
Increased
13
Reduced
13
Closed
16

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$25.4M
2
VSTM icon
Verastem
VSTM
+$22.7M
3
PCVX icon
Vaxcyte
PCVX
+$20.7M
4
LBRX
LB Pharmaceuticals
LBRX
+$17.9M
5
ARVN icon
Arvinas
ARVN
+$17.3M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$30M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$26.5M
3
UTHR icon
United Therapeutics
UTHR
+$24.4M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$18.9M
5
KROS icon
Keros Therapeutics
KROS
+$17M

Sector Composition

Rank Sector Weight
1 Healthcare 90.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$40B
$81.7M 7.33%
1,750,000
+50,000
+3% +$1.96M
IDYA icon
2
IDEAYA Biosciences
IDYA
$3.5B
$61.2M 5.49%
2,250,000
-1,095,000
-33% -$26.5M
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$57M 5.11%
1,200,000
– –
ARVN icon
4
Arvinas
ARVN
$535M
$47.5M 4.26%
5,575,000
+2,275,000
+69% +$17.3M
RVMD icon
5
CALL
Revolution Medicines
RVMD
$40B
$46.7M 4.19%
+1,000,000
New +$39.2M
OCUL icon
6
Ocular Therapeutix
OCUL
$1.91B
$38M 3.41%
3,250,000
+1,050,000
+48% +$12.6M
CDTX
7
DELISTED
Cidara Therapeutics
CDTX
$35.9M 3.22%
375,000
+185,000
+97% +$11.8M
VSTM icon
8
Verastem
VSTM
$560M
$35.8M 3.21%
4,050,000
+3,050,000
+305% +$22.7M
ABVX
9
Abivax
ABVX
$11.2B
$35.2M 3.16%
+415,000
New +$25.4M
ERAS icon
10
Erasca
ERAS
$6.63B
$33M 2.96%
15,150,000
+150,000
+1% +$239K
MAZE
11
Maze Therapeutics
MAZE
$1.57B
$31.8M 2.85%
1,227,300
+615,386
+101% +$10.4M
OLMA icon
12
Olema Pharmaceuticals
OLMA
$1.07B
$31.4M 2.82%
3,208,875
– –
IMCR icon
13
Immunocore
IMCR
$1.78B
$30.9M 2.77%
850,000
+275,000
+48% +$9.34M
DYN icon
14
Dyne Therapeutics
DYN
$4.2B
$30.4M 2.72%
2,400,000
+500,000
+26% +$5.7M
IRON icon
15
Disc Medicine
IRON
$2.86B
$29.7M 2.67%
450,000
-250,000
-36% -$14.9M
DSGN icon
16
Design Therapeutics
DSGN
$748M
$27.5M 2.47%
3,655,000
-562,627
-13% -$2.82M
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$16B
$26.4M 2.36%
200,000
-250,000
-56% -$30M
RNAM
18
DELISTED
Avidity Biosciences
RNAM
$26.1M 2.34%
600,000
-350,000
-37% -$14.1M
GPCR icon
19
Structure Therapeutics
GPCR
$3.53B
$23.8M 2.13%
850,000
– –
JANX icon
20
Janux Therapeutics
JANX
$945M
$22.9M 2.05%
935,000
-65,000
-7% -$1.58M
APLS
21
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$22.6M 2.03%
1,000,000
– –
PCVX icon
22
Vaxcyte
PCVX
$8.05B
$22.5M 2.02%
+625,000
New +$20.7M
RYTM icon
23
Rhythm Pharmaceuticals
RYTM
$7.21B
$20.2M 1.81%
200,000
+70,000
+54% +$6.5M
TRVI icon
24
Trevi Therapeutics
TRVI
$2.58B
$20.1M 1.8%
2,200,000
+1,350,000
+159% +$10.1M
PTGX icon
25
Protagonist Therapeutics
PTGX
$8.87B
$19.9M 1.79%
+300,000
New +$17.1M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2025 Portfolio in Review

As of Q3 2025, Logos Global Management held 75 positions worth $1.12B, up 23% from $904M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Logos Global Management withdrew a net $46.3M in Q3 2025, closing 16 positions and reducing 13 holdings. Its most notable exit was United Therapeutics, an estimated $24.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 83% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Abivax worth $35.2M.

  • Logos Global Management's largest Q3 2025 buy was Abivax: 415,000 shares worth $35.2M.
  • Logos Global Management added most to Verastem in Q3 2025, an estimated $22.7M increase.
  • Logos Global Management's biggest Q3 2025 reduction was Jazz Pharmaceuticals, cutting an estimated $30M.
  • Logos Global Management fully exited United Therapeutics in Q3 2025, selling an estimated $24.4M.
  • Logos Global Management's ten largest holdings make up 42% of its $1.12B portfolio in Q3 2025.
  • Logos Global Management opened 24 new positions and closed 16 in Q3 2025.
  • Logos Global Management's portfolio value rose 23% quarter-over-quarter to $1.12B.

Based on Logos Global Management's 13F filing for Q3 2025, filed 14 Nov 2025.